T. Radivoyevitch

The paper identifies a mesenchymal tumor cell state that increases dependency on BCL-XL in kidney cancer, showing anti-tumor efficacy of a BCL-XL inhibitor.

The paper develops a mouse model to study how surgery and steroids affect immune responses in glioblastoma, finding systemic lymphocyte reduction and correlations with tumor growth and patient outcomes.

This paper identifies adaptive metabolic responses in pyrimidine metabolism as a mechanism of resistance to decitabine and 5-azacytidine, and shows that alternating these drugs with metabolic inhibitors can extend DNMT1 depletion and delay leukemia relapse.

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.